Find the right bone cancer treatment regimen with detailed instructions on selection, dosing, and administration of anti-cancer agents such as vincristine.
Racial minorities are poorly represented in genomic research databases, raising important questions about whether or not all patients will benefit equally from advances in precision oncology.
New findings bolster the case for the predictive utility of ARID1A mutations.
Liquid Biopsies and Cancer Detection: New Test Assesses Levels of Circulating Proteins for Early-Stage DiagnosisJune 19, 2018
A new test has been shown to be capable of identifying eight different cancers by assessing levels of circulating proteins along with mutations in cell-free DNA.
Understanding Telomerase: Higher Quality Images Give Insight Into Developing New Agents for InhibitionJune 18, 2018
Telomerase plays a crucial role in tumor proliferation, and a better understanding of its structure will pave the way for new drug development.
Many clinical trials and systematic reviews note that the use of cannabinoids also comes with adverse events, including a clinical entity that has been gaining evidence in the literature over the last decade called cannabinoid hyperemesis syndrome.
Emerging evidence shows that injecting tumors directly into one tumor can trigger systemic antitumor immunity and immune attacks on untreated tumors elsewhere in the body.
While a recent discovery of a series of communicable cancers has raised concerns, there has been no sign of readily transmittable cancer in people that could spread through a population the way the ones found in other species do.
Researchers plan to initiate a phase 2 trial of the vaccine, which will enroll up to 25 patients with metastatic chordoma.
Researchers are hotly pursuing 2 distinct biological paths that show remarkable promise in the hunt for an effective anticancer vaccine.
Many HIV-associated cancers develop with the help of oncoviruses — some of which are sexually transmitted.
Most tumors do not respond, or evolve resistance, to immune checkpoint inhibition. Now, researchers at Johns Hopkins have engineered a new class of cancer immunotherapy agents designed to short-circuit key mechanisms of tumors' disruption and evasion of immune system attack.
Phase 1 trials should be considered therapeutic options for some patients.
The risk should not discourage patients with cancer from taking these potentially life-extending therapies.
To help curb drug prices, a consortium of hospital groups recently announced plans to form their own nonprofit drug company.
Larotrectinib may have durable antitumor activity in patients with TRK fusion-positive cancers, regardless of tumor type.
The #MeToo movement has inspired many women to relate stories of harassment, and medicine is no exception.
The novelty of immunotherapies means that physicians and patients lack extensive experience dealing with them.
A recent study is the first to demonstrate the cumulative effect of a large number of lifestyle behaviors.
As oncologists learn to target the immune response to "self and non-self," a delicate therapy balance will eventually be achieved with predictable outcomes, benefits, and toxicity in the fight against cancer.
Careful research is needed to ensure that immunotherapies activating T cells do not inadvertently fuel progression of T cell malignancies.
While some researchers are attempting to determine whether cannabis has any anti-tumor activity, the FDA recommends that patients do not listen to websites touting the benefits of cannabidiol.
Researchers hope to define what constitutes a functionally healthy microbiome not just in cancer, but across the health spectrum.
The drug addiction strategy must be broadened to account for non-addicted cells, sensitive or resistant, that remain after therapy. Much as selection should favor the development of drug resistant tumor cell lineages, it should also favor lineages that are resistant to addiction.
A class of DUBs known as the ubiquitin-specific-processing proteases are involved in regulating the p53 signaling pathway and have been implicated in tumorigenesis and radiotherapy resistance.
A recent study into the relationship between glucose and cancer cell proliferation may be helping to identify a therapeutic route to starve tumors without killing normal cells.
In part 2 of a 2-part series, Bryant Furlow discusses advances in genome sequencing technologies and the resulting insights into associations between inherited germline mutations and cancer.
From anxiety and pain self-management to side effect monitoring in clinical trials, mobile applications are revolutionizing oncology. Researchers say the technology is even transforming clinical trials themselves.
Clifford Pukel, MD, discusses from an immunological standpoint the mysterious phenomenon of spontaneous regression.
The high cost of CAR-T therapy concerns patient advocates who worry about the "financial toxicity" implications for patients and their families. But these cancer immunotherapies might offer an excellent value for clinical oncology, proponents claim.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- FDA Approves Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer
- Aggressive Follow-Up Imaging in Breast Cancer Is Geography-Specific
- Massage and Cancer
- Pembrolizumab May Lead to Favorable Long-Term Outcomes in Head and Neck Cancer
- Biomarker-Based Blood Test May Extend Reach of CT Screening for Certain Lung Cancers